Nick Thatcher - Department of Medical Oncology, The Christie Hospital

基本信息

浏览量：54

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 346 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Statistical Controversies in Clinical Research: Futility Analyses in Oncology–lessons on Potential Pitfalls from a Randomized Controlled Trial

E. Lesaffre,M. J. Edelman,N. H. Hanna, K. Park,N. Thatcher,S. Willemsen,B. Gaschler-Markefski,R. Kaiser,C. Manegold

Annals of Oncology（2017）

引用12浏览0WOS引用

Tecemotide in Unresectable Stage III Non-Small-cell Lung Cancer in the Phase III START Study: Updated Overall Survival and Biomarker Analyses

P. Mitchell,N. Thatcher,M. A. Socinski,E. Wasilewska-Tesluk,K. Horwood,A. Szczesna,C. Martin,Y. Ragulin,M. Zukin,C. Helwig,M. Falk,C. Butts,F. A. Shepherd

Annals of oncology（2015）

引用89浏览0WOS引用

Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

N. Thatcher,T. -E. Ciuleanu,R. Ramlau,C. Schumann,L. Paz-Ares,H. Depenbrock,S. Nanda,N. Chouaki,M. Socinski

Annals of Oncology（2015）

引用4浏览0引用

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (Sq-Nsclc) (SQUIRE)

M. A. Socinski,N. Thatcher,A. V. Luft,A. Szczesna,T. Ciuleanu, W. Szafranski,R. Ramlau,B. Balint,A. Kazarnowicz,O. Molinier,H. Depenbrock,S. Nanda,C. Obasaju,L. Paz-Ares

International Journal of Radiation OncologyBiologyPhysicsno. 5 (2014): S31-S32

引用0浏览0引用

1267PQUALITY-OF-LIFE (QOL), TOLERABILITY, AND SUPPORTIVE CARE RESULTS: NECITUMUMAB PHASE 3 SQUIRE STUDY

M. Reck,M. Socinski,A. Luft,A. Szczesna,M. Dediu,R. Ramlau,G. Losonczy,O. Molinier,C. Schumann, J. Brown,V. Soldatenkova,N. Chouaki,N. Thatcher

Annals of Oncology (2014)

引用0浏览0引用

A Phase II Study of Erlotinib in Combination with Bevacizumab Versus Chemotherapy Plus Bevacizumab in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer

T. Ciuleanu,C. -M. Tsai,C. -J. Tsao,J. Milanowski,D. Amoroso, D. S. Heo,H. J. M. Groen,A. Szczesna,C. -Y. Chung,T. -Y. Chao,G. Middleton,A. Zeaiter,G. Klingelschmitt,B. Klughammer,N. Thatcher

Lung Cancerno. 2 (2013): 276-281

引用39浏览0WOS引用

Talactoferrin Alfa Versus Placebo in Patients with Refractory Advanced Non-Small-cell Lung Cancer (FORTIS-M Trial)

S. Ramalingam,J. Crawford,A. Chang,C. Manegold, R. Perez-Soler,J. -Y. Douillard,N. Thatcher,F. Barlesi,T. Owonikoko, Y. Wang, P. Pultar, J. Zhu,R. Malik,G. Giaccone

Annals of Oncologyno. 11 (2013): 2875-2880

引用53浏览0WOS引用

Updated analysis and secondary endpoints with L-BLP25 in unresectable stage III non-small cell lung cancer in the phase III START study

F. Shepherd,M. Socinski,P. Mitchell,N. Thatcher,L. Havel,M. Krzakowski,S. Nawrocki,C. Helwig,A. Schroeder,C. Butts

EUROPEAN JOURNAL OF CANCER（2013）

引用0浏览0引用

Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group

S.S. Ramalingam,J. Crawford,A. Chang,C. Manegold,R. Perez-Soler,J. Douillard,N. Thatcher,F. Barlesi,T.K. Owonikoko, Y. Wang, P. Pultar, J. Zhu,R. Malik,G. Giaccone

Annals of Oncology（2012）

引用4浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn